What percentage of US adults will claim to be currently taking GLP-1 drugs for weight loss in 2030?

TL;DR

My median forecast is 19% of U.S. adults, with an 80% interval of 12% to 28%. Current use rose from 3% in 2024 to 11% in 2026, and oral drugs plus temporary Medicare access push the 2030 value higher (Gallup 2026, FDA 2026, CMS 2026). The 2024-2026 surge does not continue linearly because awareness is already high, payer controls are tight, compounded supply is legally exposed, and discontinuation is common (Gallup 2026, KFF Employer Survey 2025, FDA Compounding 2026, JAMA Network Open 2025).

Context

Gallup's July 7, 2026 release is the anchor for this question: 11% of U.S. adults said they were currently taking GLP-1 medications for weight loss, 15% said they had ever used them for weight loss, and the probability-based Gallup Panel survey covered 5,065 adults from May 28 to June 5, 2026 with a ±1.5 percentage point full-sample margin of error (Gallup 2026). The resolution statistic is a self-reported point-in-time stock, not prescriptions, claims, manufacturer sales, or lifetime trial.

The access environment is moving in both directions. FDA-approved oral weight-loss GLP-1s are now real, with the Wegovy pill approved in December 2025 and Lilly's oral orforglipron, Foundayo, approved on April 1, 2026 (Novo Nordisk 2025, FDA 2026). At the same time, the Medicare GLP-1 Bridge runs only from July 1, 2026 through December 31, 2027, Medicaid obesity coverage is limited, and employers are using prior authorization and other controls to contain spending (CMS 2026, KFF Medicare 2026, KFF Medicaid 2026, KFF Employer Survey 2025).

Evidence

The historical backbone is short. The full comparable Gallup series is:

A straight line through 2024-2026 gives a 2030 value near 27%, but that is too mechanical. The annual gain slowed from +5 points to +3 points, and Gallup already found 91% awareness of GLP-1 drugs for weight loss in 2026, up from 80% in 2024 (Gallup 2026). A separate Gallup article reported 12.4% current use of this class specifically for weight loss in Q2-Q3 2025, versus 5.8% in February 2024, so survey wording and harmonization can move the measured level by several points (Gallup 2025).

Other surveys confirm the scale. KFF found current GLP-1 use for any reason at 6% in May 2024 and 12% in its October 27-November 2, 2025 Health Tracking Poll, with ever-use rising from 12% to 18% over the same comparison (KFF May 2024, KFF November 2025). NORC's February 2026 AmeriSpeak survey found 14% ever-use and 9% current use for GLP-1s overall, with 70% of users citing weight loss as a reason (NORC 2026). The addressable pool is not the binding constraint: CDC/NCHS measured-height-and-weight NHANES data for August 2021-August 2023 found 40.3% obesity among U.S. adults age 20 and older, including 9.7% severe obesity, plus another 31.7% overweight, with a latest-cycle adult sample of 5,929 (CDC/NCHS 2026).

The adoption tailwinds are large. Oral products remove injection friction, and IQVIA's April 2026 obesity outlook put global obesity-medicine list-price sales at $66 billion in 2025 and forecast $92 billion in 2026, with the 2027-and-beyond range at $105 billion to $200 billion (IQVIA 2026). Public coverage also moved: CMS says eligible Part D beneficiaries can get certain GLP-1s for weight management for $50 per month through the Medicare GLP-1 Bridge until December 31, 2027, and KFF estimates 3.8 million Medicare beneficiaries met the new bridge criteria using 2023 claims data (CMS 2026, KFF Bridge Eligibility 2026).

The adoption brakes are also large. KFF reported that only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026, down from 16 in October 2025 after several states ended coverage (KFF Medicaid 2026). KFF's 2025 employer survey found that 19% of firms with at least 200 workers covered GLP-1 agonists primarily for weight loss in their largest plan, including 43% of firms with at least 5,000 workers (KFF Employer Survey 2025). A 2026 Business Group on Health survey of 105 large-employer members found 67% covered GLP-1s for weight management, but only 72% of covering employers said they were likely to continue in 2027, and 87% expected oral GLP-1s to raise demand (Business Group on Health 2026).

Persistence is the main reason current use does not converge quickly toward the overweight-or-obese share of the population. A JAMA Network Open cohort of 125,474 adults with overweight or obesity who initiated dual-labeled GLP-1 receptor agonists from 2018 through 2023 found 64.8% one-year discontinuation among patients without type 2 diabetes and 46.5% among patients with type 2 diabetes, with 36.3% and 47.3% reinitiating within a year after discontinuation, respectively (JAMA Network Open 2025). A later commercially insured study of high-potency, weight-loss-indicated GLP-1 initiators without diabetes found one-year persistence improved from 33.2% for 2021 initiators to 60.9% for first-half 2024 initiators, which points to improving but still imperfect retention (JMCP 2026). Blue Cross Blue Shield research based on nearly 170,000 commercial-plan members found 58% discontinued before reaching clinically meaningful benefit (BCBS 2024).

My stock-flow check uses $p_{t+1}=r p_t+i_t$, where $p_t$ is current use, $r$ is effective annual retention including restarts, and $i_t$ is gross new or returning current use as a share of adults. With Gallup's 8% in 2025 and 11% in 2026, a plausible retention range of 65% to 80% implies a 2025-2026 gross inflow of 4.6 to 5.8 percentage points of adults. If that inflow persists near 5 to 6 points and effective retention sits near 65% to 75%, the 2030 stock lands in the high teens or low 20s; oral drugs, durable public coverage, or a price break move it higher, while loss of compounded supply and payer pullback move it lower.

I used a four-scenario mixture. The restrictive scenario gets 18% weight and centers near 12%, covering loss of cheap compounded access, a post-2027 Medicare cliff, and high churn; this matters because Gallup found 19% of 2026 current users were on compounded or custom-mixed products, and FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (Gallup 2026, FDA Compounding 2026). The base managed-diffusion scenario gets 52% weight and centers near 18.5%, with strong starts but persistent cost controls. The oral-and-coverage upside scenario gets 24% weight and centers near 25%, with better persistence and broader commercial or public access. The mass-market price-break scenario gets 6% weight and centers near 33.5%.

As a calibration check, outside projections point to growth but not to universal use. J.P. Morgan estimated that more than 30 million Americans will be on GLP-1 treatment in 2030, up about 10 million from 2026 branded GLP-1 use, while Morgan Stanley's 2026 base case put U.S. GLP-1 treatment penetration near 30% of the obese-or-diabetic population by 2035, up from about 6% in 2025 (J.P. Morgan 2026, Morgan Stanley 2026). Since Gallup's 2026 self-report includes brand-name, compounded, unsure, cash-pay, and loosely interpreted weight-loss use, those projections support a 2030 Gallup value in the teens or 20s, not a 30%+ median.

What's non-obvious

The 11% Gallup number is already much bigger than many prescription-market frames imply. Gallup found only 68% of current users reported a brand-name prescription, 19% reported compounded or custom-mixed medication, and 12% were unsure which type they used (Gallup 2026). That means a claims-only or branded-user forecast can miss a large part of the Gallup outcome, but it also means the 2026 level contains a low-cost access channel that may not survive in its current form.

The second trap is treating current use like cumulative adoption. Ever-use can keep rising fast while current use grows slowly if many people stop, restart, or cycle through lower doses. The current-use stock can still rise from 11% to about 19% by 2030 with heavy churn, but a value above 30% needs three things at once: cheap oral supply, durable coverage, and much better persistence than early real-world data show.

Limitations

Gallup has only three comparable annual points in the target series, and its own 2025 reporting differs across articles, with one article giving 12.4% current use for Q2-Q3 2025 while the later comparable table gives 8% for 2025 (Gallup 2025, Gallup 2026). The 2030 article could also change examples, include oral drugs more explicitly, or report a decimal instead of the whole percentages used in the 2024-2026 comparable table.

The biggest unresolved driver is policy after 2027. CMS says the Medicare GLP-1 Bridge ends on December 31, 2027, and KFF describes the broader BALANCE path as delayed and budget-sensitive rather than settled (CMS 2026, KFF Medicare 2026). The other large gaps are the post-enforcement size of the compounded market, the real-world uptake of oral products, and the bridge between self-report survey answers and pharmacy or claims data.